Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Pulmonary Embolism Pipeline Review, H2 2016 - Analysis, Technologies & Forecasts - Key Vendors: Accu-Break Pharmaceuticals, Dong-A Socio Holdings Co, F. Hoffmann-La Roche Ltd - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Pulmonary Embolism - Pipeline Review, H2 2016" drug pipelines to their offering.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
  • The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism

Companies Mentioned:

  • Accu-Break Pharmaceuticals, Inc.
  • Dong-A Socio Holdings Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/rn2g7d/pulmonary

Related Topics: Cardiovascular Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005728/en/

Business Wire
www.businesswire.com

Last updated on: 19/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.